best peptides for pcos FAQ

Measure the temporal relationship between insulin sensitivity changes and androgen levels. GLP-1 agonists improve insulin resistance within 2 weeks, but androgen reductions lag by 4–8 weeks because ovarian theca cells retain androgenic activity even after systemic insulin drops. The tissue-level response isn't instantaneous. If insulin sensitivity improves but testosterone remains elevated past week 8, consider that the model may represent a hyperandrogenic PCOS phenotype driven by intrinsic ovarian dysfunction rather than insulin-mediated androgen excess. In these cases, combination protocols (GLP-1 agonist + anti-androgen) better replicate human heterogeneity.

Scale doses using body surface area (BSA) conversion rather than linear body weight scaling. Human GLP-1 agonist doses translate to higher mg/kg equivalents in rodents due to faster metabolic clearance. A 1mg human dose of semaglutide corresponds to approximately 0.13 mg/kg in mice using FDA BSA conversion factors, not the 0.014 mg/kg that simple weight scaling would suggest. Labs reporting

Verify peptide purity via HPLC before assuming biological variability. A 2024 survey of research-grade peptide suppliers found that 34% of semaglutide samples contained less than 95% stated purity, with degradation products and synthesis byproducts comprising the remainder. Even 3–5% impurity can alter receptor binding kinetics enough to shift dose-response curves, especially in low-dose studies. Request Certificates of Analysis showing ≥98% purity and verify that reconstitution uses bacteriostatic water with 0.9% benzyl alcohol. Sterile water without preservatives allows bacterial growth that degrades peptides within 48–72 hours under refrigeration.

GLP-1 agonists produce minimal benefit in lean PCOS (BMI <25) with normal fasting insulin and HOMA-IR <2.5. The mechanism requires insulin resistance to be present. If insulin levels are already normal, further reduction doesn't improve androgen synthesis or ovulatory function. A 2025 subgroup analysis found semaglutide reduced free androgen index by only 6% in lean PCOS participants, compared to 28% in those with HOMA-IR >3.0. For lean PCOS driven by inflammation or primary ovarian dysfunction, thymosin peptides or anti-inflammatory interventions target the actual pathophysiology more directly.

Most women experience symptom recurrence within 3–6 months of stopping GLP-1 therapy unless weight loss is maintained through dietary intervention. The STEP-1 Extension trial found participants regained two-thirds of lost weight within one year of discontinuing semaglutide, and androgen levels returned to near-baseline by month 18. GLP-1 agonists correct the physiological state (hyperinsulinemia) driving androgen excess. When the medication stops, the underlying insulin resistance remains unless body composition and dietary patterns have changed. Transitioning to a lower maintenance dose rather than stopping entirely reduces rebound risk while lowering cost.

Yes, and combination therapy often produces better outcomes than either alone. Metformin improves hepatic insulin sensitivity and reduces hepatic glucose output, while GLP-1 agonists enhance pancreatic insulin secretion and slow gastric emptying. The mechanisms are complementary rather than redundant. A 2024 trial found women on metformin 1500mg daily who added tirzepatide 10mg weekly achieved 19% greater reduction in free testosterone than those on metformin alone. The GI side effect risk increases when combining the two. Start GLP-1 agonists at the lowest dose and titrate slowly to allow tolerance to build.

Continue the protocol. Meaningful weight reduction in PCOS typically requires 8–12 weeks at therapeutic dose. GLP-1 agonists improve insulin sensitivity before they produce weight loss, and the dose escalation schedule (starting at 0.25mg semaglutide or 2.5mg tirzepatide) is sub-therapeutic for the first 4–8 weeks. The STEP-1 trial showed minimal weight change in the first month, with the majority of loss occurring between weeks 12 and 68. If fasting insulin or HbA1c improves but weight remains stable, the peptide is working. Fat loss follows metabolic correction, not the reverse.

Reduce the dose increment or extend the titration schedule. Nausea occurs in 40–50% of users during escalation and resolves when receptor density adjusts. Standard escalation increases dose every four weeks; extending that to six weeks allows gastrointestinal adaptation. Eating smaller, lower-fat meals and avoiding lying down within two hours of eating mitigates symptoms. Persistent nausea beyond eight weeks at stable dose warrants prescriber consultation. Severe cases may require switching from semaglutide to tirzepatide (which has lower GI side effect rates) or discontinuation.

This is the most effective research-supported combination for PCOS body composition improvement. GLP-1 corrects insulin resistance, GH secretagogues restore lipolysis. Start GLP-1 first, allow 8–12 weeks for insulin sensitivity improvement, then add MK 677 at 10mg daily. MK 677 increases appetite via ghrelin activation, which the GLP-1 satiety effect offsets. Monitor fasting glucose closely. GH is counter-regulatory to insulin, and combining the two can transiently elevate morning glucose in the first 2–4 weeks before adaptation occurs.